Abstract: Surgical tools that are capable of both manipulating a needle and cutting surgical thread during a suturing operation can sometimes be problematic due to inadvertent severing of the surgical thread. Surgical tools capable of exposing a bladed cutting surface only when severing of surgical thread is desired can substantially alleviate this issue. Such surgical tools may comprise an end effector comprising an end effector axle, a first jaw and a second jaw rotatably mounted to the end effector axle, and a first cutting body having a first blade and second cutting body having a second blade. The first cutting body is configured to move in tandem with the first jaw and the second cutting body is configured to move in tandem with the second jaw, such that the first and second blades are occluded when the first and second jaws are closed or partially opened.

Abstract: Surgical tools that are capable of both manipulating a needle and cutting surgical thread during a suturing operation can sometimes be problematic due to inadvertent severing of the surgical thread. Surgical tools capable of exposing a bladed cutting surface only when severing of surgical thread is desired can substantially alleviate this issue. Such surgical tools may comprise an end effector comprising an end effector axle, a first jaw and a second jaw rotatably mounted to the end effector axle, and a first cutting body having a first blade and second cutting body having a second blade. The first cutting body is configured to move in tandem with the first jaw and the second cutting body is configured to move in tandem with the second jaw, such that the first and second blades are occluded when the first and second jaws are closed or partially opened.

Abstract: A method of operating a surgical tool includes mounting the surgical tool to a tool driver. The surgical tool includes one or more drive cables movable to actuate an end effector, and one or more segments are defined along a portion of at least one of the one or more drive cables and each segment exhibits a usage value. Usage of the drive cables is monitored with a computer system in communication with the tool driver, and the usage value of one or more of the segments is altered based on usage of the surgical tool.

Abstract: Surgical tools that are capable of both manipulating a needle and cutting surgical thread during a suturing operation can sometimes be problematic due to inadvertent severing of the surgical thread. Surgical tools capable of exposing a bladed cutting surface only when severing of surgical thread is desired can substantially alleviate this issue. Such surgical tools may comprise an end effector comprising an end effector axle, a first jaw and a second jaw rotatably mounted to the end effector axle, and a first cutting body having a first blade and second cutting body having a second blade. The first cutting body is configured to move in tandem with the first jaw and the second cutting body is configured to move in tandem with the second jaw, such that the first and second blades are occluded when the first and second jaws are closed or partially opened.

Abstract: Surgical tools that are capable of both manipulating a needle and cutting surgical thread during a suturing operation can sometimes be problematic due to inadvertent severing of the surgical thread. Surgical tools capable of exposing a bladed cutting surface only when severing of surgical thread is desired can substantially alleviate this issue. Such surgical tools may comprise an end effector comprising an end effector axle, a first jaw and a second jaw rotatably mounted to the end effector axle, and a first cutting body having a first blade and second cutting body having a second blade. The first cutting body is configured to move in tandem with the first jaw and the second cutting body is configured to move in tandem with the second jaw, such that the first and second blades are occluded when the first and second jaws are closed or partially opened.

Abstract: A method of operating a surgical tool includes mounting the surgical tool to a tool driver. The surgical tool includes one or more drive cables movable to actuate an end effector, and one or more segments are defined along a portion of at least one of the one or more drive cables and each segment exhibits a usage value. Usage of the drive cables is monitored with a computer system in communication with the tool driver, and the usage value of one or more of the segments is altered based on usage of the surgical tool.

Abstract: Surgical tools that are capable of both manipulating a needle and cutting surgical thread during a suturing operation can sometimes be problematic due to inadvertent severing of the surgical thread. Surgical tools capable of exposing a bladed cutting surface only when severing of surgical thread is desired can substantially alleviate this issue. Such surgical tools may comprise an end effector comprising an end effector axle, a first jaw and a second jaw rotatably mounted to the end effector axle, and a first cutting body having a first blade and second cutting body having a second blade. The first cutting body is configured to move in tandem with the first jaw and the second cutting body is configured to move in tandem with the second jaw, such that the first and second blades are occluded when the first and second jaws are closed or partially opened.

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Abstract: A surgical apparatus includes a cannula and a surgical instrument. The cannula includes a curved longitudinal axis along at least a portion of its length. The surgical instrument includes an elongated shaft having a distal end and a proximal end, and an end effector coupled to the distal end of the elongated shaft. At least a portion of the end effector is configured to contact an inner surface of the cannula during insertion of the surgical instrument into the curved cannula. A threshold galling stress between the portion of the end effector and an inner surface of the curved cannula is at least 10,000 pounds per square inch.

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Abstract: Methods and apparatuses to automatically modify a circuit design (e.g., a synthesis solution) according to the sensitivity in design parameters with respect to the possible deviation in the subsequent implementation (e.g., placement and routing) of the circuit. In one aspect of the present invention, a method to design a circuit includes: determining likelihood of a design constraint being violated in an implementation of a first circuit design (e.g., a technology specific netlist with or without a placement solution); and, modifying the first circuit design to reduce the likelihood of the design constraint being violated. In one example, the implementation of the first circuit design includes a routing solution for implementing the first circuit design; and, the first circuit is modified through sizing an instance of a logic element, buffering a signal, load shielding for a signal, or other operations.

Abstract: A surgical apparatus includes a cannula and a surgical instrument. The cannula includes a curved longitudinal axis along at least a portion of its length. The surgical instrument includes an elongated shaft having a distal end and a proximal end, and an end effector coupled to the distal end of the elongated shaft. At least a portion of the end effector is configured to contact an inner surface of the cannula during insertion of the surgical instrument into the curved cannula. A threshold galling stress between the portion of the end effector and an inner surface of the curved cannula is at least 10,000 pounds per square inch.

Abstract: Methods and apparatuses to automatically modify a circuit design (e.g., a synthesis solution) according to the sensitivity in design parameters with respect to the possible deviation in the subsequent implementation (e.g., placement and routing) of the circuit. In one aspect of the present invention, a method to design a circuit includes: determining likelihood of a design constraint being violated in an implementation of a first circuit design (e.g., a technology specific netlist with or without a placement solution); and, modifying the first circuit design to reduce the likelihood of the design constraint being violated. In one example, the implementation of the first circuit design includes a routing solution for implementing the first circuit design; and, the first circuit is modified through sizing an instance of a logic element, buffering a signal, load shielding for a signal, or other operations.

Abstract: Methods and apparatuses to automatically modify a circuit design (e.g., a synthesis solution) according to the sensitivity in design parameters with respect to the possible deviation in the subsequent implementation (e.g., placement and routing) of the circuit. In one aspect of the present invention, a method to design a circuit includes: determining likelihood of a design constraint being violated in an implementation of a first circuit design (e.g., a technology specific netlist with or without a placement solution); and, modifying the first circuit design to reduce the likelihood of the design constraint being violated. In one example, the implementation of the first circuit design includes a routing solution for implementing the first circuit design; and, the first circuit is modified through sizing an instance of a logic element, buffering a signal, load shielding for a signal, or other operations.

Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R5, m and J are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.

Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R1, R2, and R5 are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.

Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R5 and J are defined herein, are useful in the treatment of cancer.

Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.

Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.

Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A and J are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.